Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ADC Therapeutics (ADCT) EBITDA Margin (2019 - 2026)

ADC Therapeutics has reported EBITDA Margin over the past 8 years, most recently at 126.02% for Q1 2026.

  • Quarterly results put EBITDA Margin at 126.02% for Q1 2026, up 44326.0% from a year ago — trailing twelve months through Mar 2026 was 216.07% (up 2452.0% YoY), and the annual figure for FY2022 was 2070430.86%, up 207111554.0%.
  • EBITDA Margin reached 126.02% in Q1 2026 per ADCT's latest filing, up from 196.63% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 18760.78% in Q3 2023 and bottomed at 569.28% in Q1 2025.
  • Median EBITDA Margin over the past 5 years was 183.58% (2024), compared with a mean of 2073.42%.
  • The largest annual shift saw EBITDA Margin soared 2000000000bps in 2022 before it tumbled -1895818bps in 2024.
  • Over 5 years, EBITDA Margin stood at 6.23% in 2022, then soared by 301203bps to 18760.78% in 2023, then tumbled by -101bps to 197.4% in 2024, then increased by 0bps to 196.63% in 2025, then soared by 36bps to 126.02% in 2026.
  • Business Quant data shows EBITDA Margin for ADCT at 126.02% in Q1 2026, 196.63% in Q3 2025, and 234.34% in Q2 2025.